Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Epilepsy Research|September 7, 2016
Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizuresVicente Villanueva, Oneeb Majid, Charcrin Nabangchang, et al.Clinical Therapeutics|October 4, 2016
Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release TabletRonald Christopher, Mike Morgan, Jim Ferry, et al.Clinical Pharmacology in Drug Development|May 30, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy AdultsIshani Landry, Kenya Nakai, Jim Ferry, et al.Epilepsy Research|May 24, 2017
Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design mattersBarry E Gidal, Rama Maganti, Antonio Laurenza, et al.Neurology|April 17, 2015
Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsyBarry E Gidal, Antonio Laurenza, Ziad Hussein, et al.Journal of Clinical Pharmacology|December 18, 2013
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjectsYanke Yu, Veronika Logovinsky, Edgar Schuck, et al.Epilepsy & Behavior : E&B|May 3, 2014
The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studiesBarry E Gidal, Oneeb Majid, Jim Ferry, et al.Journal of Clinical Pharmacology|June 25, 2016
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of LemborexantPatricia J Murphy, Sanae Yasuda, Kenya Nakai, et al.Journal of Child Neurology|February 12, 2019
Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to <12 Years of Age With Epilepsy: Pharmacokinetics, Safety, Tolerability, and EfficacyJ Ben Renfroe, Mark Mintz, Ronald Davis, et al.British Journal of Clinical Pharmacology|January 18, 2018
Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugsMaiko Nomoto, Cynthia A Zamora, Edgar Schuck, et al.Pageof 3